PRT2527 + Zanubrutinib + Venetoclax

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 19/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)

Conditions

Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Mantle Cell Lymphoma (MCL), Richter's Syndrome, T-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Marginal Zone Lymphoma, Myeloid Malignancies, Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome (MDS), MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome

Trial Timeline

Sep 12, 2023 → Jan 21, 2026

NCT ID

NCT05665530

About PRT2527 + Zanubrutinib + Venetoclax

PRT2527 + Zanubrutinib + Venetoclax is a phase 1 stage product being developed by Prelude Therapeutics for Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL). The current trial status is completed. This product is registered under clinical trial identifier NCT05665530. Target conditions include Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Mantle Cell Lymphoma (MCL).

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05665530	Phase 1	Completed	Sep 12, 2023	Jan 21, 2026	Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)

Competing Products

11 competing products in Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)

See all competitors

Product	Company	Stage	Hype Score
ACALABRUTINIB + LISOCABTAGENE MARALEUCEL + Lymphodepleting chemotherapy	Johnson & Johnson	Phase 2	39
Loncastuximab Tesirine and Epcoritamab	AbbVie	Phase 2	42
Cabazitaxel + Carboplatin + Prednisone 5Mg + Olaparib	AstraZeneca	Phase 2	39
Midostaurin	Novartis	Phase 2	35
Imatinib	Novartis	Phase 2	35
Bendamustine and subcutaneous rituximab	Roche	Phase 2	35
Cyclophosphamide + Doxorubicin Hydrochloride + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate	Bristol Myers Squibb	Phase 1/2	36
Cyclophosphamide + Doxorubicin Hydrochloride + Etoposide + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate	Bristol Myers Squibb	Phase 2	39
Vandetanib 300 mg	Sanofi	Pre-clinical	26
cemiplimab + odronextamab	Regeneron Pharmaceuticals	Phase 1	33
Zanzalintinib	Exelixis	Phase 2	39